CN112194575A - Modified compound of marine antibiotic and application thereof - Google Patents
Modified compound of marine antibiotic and application thereof Download PDFInfo
- Publication number
- CN112194575A CN112194575A CN202011015799.3A CN202011015799A CN112194575A CN 112194575 A CN112194575 A CN 112194575A CN 202011015799 A CN202011015799 A CN 202011015799A CN 112194575 A CN112194575 A CN 112194575A
- Authority
- CN
- China
- Prior art keywords
- compound
- marine
- application
- staphylococcus aureus
- methicillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 23
- 230000003115 biocidal effect Effects 0.000 title description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 12
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims abstract description 11
- 229960003085 meticillin Drugs 0.000 claims abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract description 6
- 229940088710 antibiotic agent Drugs 0.000 abstract description 5
- 230000003013 cytotoxicity Effects 0.000 abstract description 4
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 108010087702 Penicillinase Proteins 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229950009506 penicillinase Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001279361 Stachybotrys Species 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
- C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of antibiotics, in particular to a modified compound of marine antibiotics and application thereof. A compound of formula (I):
Description
Technical Field
The invention relates to the field of antibiotics, in particular to a modified compound of marine antibiotics and application thereof.
Background
Methicillin-resistant staphylococcus aureus is a clinically common bacterium with strong toxicity, and since penicillin appeared in the last 40 th century, infectious diseases caused by staphylococcus aureus are greatly controlled. However, with the widespread use of penicillin, some staphylococcus aureus produces penicillinase, which hydrolyzes the β -lactam ring and is manifested as penicillin-resistant. Scientists have developed a new semi-synthetic penicillin that is resistant to penicillinase, methicillin (methicillin).
After clinical application in 1959, the infection of staphylococcus aureus enzyme-producing strains is effectively controlled, methicillin-resistant staphylococcus aureus (MRSA) is discovered for the first time by Jevons in the UK, and the MRSA is discovered to be infected almost globally from now and becomes one of important pathogenic bacteria of nosocomial and community infection.
Disclosure of Invention
The invention aims to provide a modified compound of marine antibiotics and application thereof to overcome the defects of the prior art.
The technical scheme adopted by the invention for solving the technical problem is as follows:
the invention provides a compound which is shown as a formula (I):
the compound (I) has antibacterial ability.
The application of one compound is as follows: the compounds are useful for inhibiting methicillin-resistant staphylococcus aureus.
Further, the compound is used as a preparation ingredient for treating a patient with methicillin-resistant staphylococcus aureus, and further comprises pharmaceutically acceptable auxiliary materials.
The invention has the advantages that: has strong antibacterial ability to methicillin-resistant staphylococcus aureus, excellent antibacterial activity and less cytotoxicity.
Detailed Description
In order to make the technical means, the creation characteristics, the achievement purposes and the effects of the invention easy to understand, the invention is further described with the specific embodiments.
Example 1
A natural fungicidal compound is purified from an alcoholic extract of the marine fungus Stachybotrys pMF347, of the formula:
the compound (I) is obtained by structural modification thereof.
Selecting methicillin-resistant staphylococcus aureus, and respectively carrying out antibacterial activity and cytotoxicity determination on the natural bactericidal compound and the compound (I). The specific results are as follows:
in conclusion, it was shown that compound (i) has better antibacterial activity and, less cytotoxicity. Has great significance for treating infected patients.
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are given by way of illustration of the principles of the present invention, and that various changes and modifications may be made without departing from the spirit and scope of the invention as defined by the appended claims. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (3)
1. A compound of formula (I):
the compound (I) has antibacterial ability.
2. Use of a compound according to claim 1, wherein: the compounds are useful for inhibiting methicillin-resistant staphylococcus aureus.
3. Use of a compound according to claim 2, characterized in that: the compound is used as a preparation component for treating a patient with methicillin-resistant staphylococcus aureus, and further comprises pharmaceutically acceptable auxiliary materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011015799.3A CN112194575A (en) | 2020-09-24 | 2020-09-24 | Modified compound of marine antibiotic and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011015799.3A CN112194575A (en) | 2020-09-24 | 2020-09-24 | Modified compound of marine antibiotic and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112194575A true CN112194575A (en) | 2021-01-08 |
Family
ID=74016181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011015799.3A Pending CN112194575A (en) | 2020-09-24 | 2020-09-24 | Modified compound of marine antibiotic and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112194575A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101543499A (en) * | 2008-03-25 | 2009-09-30 | 河南大学 | Application of natural compound ursolic acid on antibiosis |
| CN103333148A (en) * | 2013-06-08 | 2013-10-02 | 中国人民解放军第四军医大学 | 3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin and application thereof in preparation of medicine for resisting multi-drug resistant bacteria |
| CN104788413A (en) * | 2014-01-20 | 2015-07-22 | 复旦大学 | New lignin type compound and its application in preparation of synergistic drug resistant staphylococcus aureus resistance drugs |
| CN105476983A (en) * | 2015-11-30 | 2016-04-13 | 国家海洋局第三海洋研究所 | Application of deep sea fungus derived compound Prenylcandidusin C |
| CN107951870A (en) * | 2016-10-14 | 2018-04-24 | 复旦大学 | A kind of pharmaceutical composition of the suppression drug-resistant staphylococcus aureus containing resveratrol |
| CN110025612A (en) * | 2019-05-23 | 2019-07-19 | 吉林大学 | Application of the Chrysin in preparation treatment methicillin-resistant staphylococcus aureus infectious pneumonia drug |
| CN111494364A (en) * | 2020-06-19 | 2020-08-07 | 中南民族大学 | Application of isopentenyl substituted phenol compound in resisting staphylococcus aureus and methicillin-resistant staphylococcus aureus |
-
2020
- 2020-09-24 CN CN202011015799.3A patent/CN112194575A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101543499A (en) * | 2008-03-25 | 2009-09-30 | 河南大学 | Application of natural compound ursolic acid on antibiosis |
| CN103333148A (en) * | 2013-06-08 | 2013-10-02 | 中国人民解放军第四军医大学 | 3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin and application thereof in preparation of medicine for resisting multi-drug resistant bacteria |
| CN104788413A (en) * | 2014-01-20 | 2015-07-22 | 复旦大学 | New lignin type compound and its application in preparation of synergistic drug resistant staphylococcus aureus resistance drugs |
| CN105476983A (en) * | 2015-11-30 | 2016-04-13 | 国家海洋局第三海洋研究所 | Application of deep sea fungus derived compound Prenylcandidusin C |
| CN107951870A (en) * | 2016-10-14 | 2018-04-24 | 复旦大学 | A kind of pharmaceutical composition of the suppression drug-resistant staphylococcus aureus containing resveratrol |
| CN110025612A (en) * | 2019-05-23 | 2019-07-19 | 吉林大学 | Application of the Chrysin in preparation treatment methicillin-resistant staphylococcus aureus infectious pneumonia drug |
| CN111494364A (en) * | 2020-06-19 | 2020-08-07 | 中南民族大学 | Application of isopentenyl substituted phenol compound in resisting staphylococcus aureus and methicillin-resistant staphylococcus aureus |
Non-Patent Citations (4)
| Title |
|---|
| JONATHAN SORRES等: "Ilicicolinic acids and ilicicolinal derivatives from the fungus Neonectria discophora SNB-CN63 isolated from the nest of the termite Nasutitermes corniger found in French Guiana show antimicrobial activity" * |
| LANGFIELD, RICHARD D.等: "Use of a modified microplate bioassay method to investigate antibacterial activity in the Peruvian medicinal plant Peperomia galioides" * |
| NIRMA, CHARLOTTE等: "Antibacterial Ilicicolinic Acids C and D and Ilicicolinal from Neonectria discophora SNB-CN63 Isolated from a Termite Nest" * |
| TOKUYAMA, SHINJI等: "Anti-MRSA and antifungal compounds from the mushroom Albatrellus dispansus (Lloyd) Canf. et Gilb. (Aphyllophoromycetideae)" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saga et al. | History of antimicrobial agents and resistant bacteria | |
| Tally et al. | In vitro activity of N-formimidoyl thienamycin (MK0787) | |
| Chin et al. | Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection | |
| Hall et al. | Comparative in-vitro activity and mode of action of ceftriaxone (Ro 13-9904), a new highly potent cephalosporin | |
| CN112194575A (en) | Modified compound of marine antibiotic and application thereof | |
| Vandenbroucke-Grauls | Epidemiology of staphylococcal infections-a European perspective | |
| EP0563844A1 (en) | Antimicrobial compositions and pharmaceutical preparations thereof | |
| KR20140035376A (en) | Compositions comprising antibacterial agent and tazobactam | |
| Matsumoto et al. | Newer carbapenems for urinary tract infections | |
| MX2021003498A (en) | Indane derivatives for use in the treatment of bacterial infection. | |
| Cohn et al. | Comparative in-vitro activity of MK0787 (N-formimidoyl thienamycin) against 540 blood culture isolates | |
| CN113082026B (en) | Application of artemisinin derivative in preparation of polymyxin antibacterial synergist | |
| Wise et al. | The antibacterial activity of meropenem in combination with gentamicin or vancomycin | |
| Jacobus et al. | Antimicrobial spectrum of Win 49375 | |
| Rylander et al. | Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria | |
| Norrby et al. | In-vitro antibacterial activity of SQ 26,776 | |
| CN101837126A (en) | Cephalosporin antibacterial combination and medicinal preparation thereof | |
| Voutsinas et al. | Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa | |
| Braveny et al. | Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin and gentamicin | |
| Norrby et al. | Comparative in vitro antibacterial activity of Sch 34343, a novel penem antibiotic | |
| Zygmunt et al. | Microbiological activities of lysostaphin and penicillins against bacteriophage 80/81 strains of Staphylococcus aureus | |
| CA1336412C (en) | Pharmaceutical composition having synergistic effect | |
| Counts et al. | Comparative in vitro activity of the new oral cephalosporin cefixime | |
| CN1706388A (en) | New antibiotic composition | |
| Watanakunakorn | Effects of inoculum size on the activity of carboxy-and ureido-penicillins and effects of combinations of ureido-penicillins with aminoglycosides against resistant Pseudomonas aeruginosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210108 |
|
| WD01 | Invention patent application deemed withdrawn after publication |